Physician profile
Thomas Michael Buzbee
NPI 1770682619
$116,211.68
in general payments reported to CMS, 2019-2025
53 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $6,223 · 2022: $32K · 2023: $12K · 2024: $21K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $5,085 · Travel and Lodging: $146 · Education: $51.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,350.00 |
| Food and Beverage | $5,084.90 |
| Travel and Lodging | $145.60 |
| Education | $51.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $104,289.30 | 2019-2025 | Repatha, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $3,921.68 | 2019-2025 | |
| Abbvie INC. | $1,471.78 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,238.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $926.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $737.56 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Regeneron Healthcare Solutions, INC. | $638.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $466.06 | 2019-2025 | |
| Astellas Pharma US INC | $278.47 | 2019-2025 | Veozah |
| Abbott Laboratories | $172.76 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $147.50 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.70 | 2019-2020 | |
| Horizon Therapeutics Plc | $143.27 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $124.52 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $120.00 | 2023 | Zilretta |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Buzbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.